SENORES vs VINEETLAB: Stock Comparison

Senores Pharmaceuticals Limited vs Vineet Laboratories Limited

Live data: 22 July 2026, 3:02 PM IST • Source: NSE and company filings

Senores Pharmaceuticals Limited is the larger company by market capitalisation. Senores Pharmaceuticals Limited shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Senores Pharmaceuticals Limited and Vineet Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, SENORES is more favourable on 9 of 10 scored metrics and VINEETLAB on 0These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SENORES is the larger company
₹6,415 Cr vs ₹73 Cr
EPS
SENORES has higher earnings per share
₹26.36 vs ₹-20.47
Revenue Growth (TTM YoY)
SENORES has faster revenue growth
53.4% vs 11.05%
EPS Growth (TTM YoY)
SENORES has faster EPS growth
108.9% vs 0%
Qtr Sales Growth
SENORES has stronger quarterly sales growth
53.4% vs -68.8%
Qtr Profit Growth
SENORES has stronger quarterly profit growth
77.3% vs 59.2%
ROCE
SENORES has a higher ROCE
15.1% vs -28%
Net Margin
SENORES has a higher net margin
18.5% vs -26.92%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSENORESVINEETLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSENORESVINEETLAB
Live Price₹1,390.4₹38.55
Day Change-0.97%5.79%
Volume3.39 L2.02 L
52-Week High₹1,509.8₹49.99
52-Week Low₹601.1₹27.96
Distance from 52W High-7.91%-22.88%

Valuation

MetricSENORESVINEETLAB
Market Cap₹6,415 Cr₹73 Cr
P/E Ratio53.33x
P/B Ratio6.94x
EPS₹26.36₹-20.47
Book Value₹235.1₹15.84
Dividend Yield0%0%

Growth

MetricSENORESVINEETLAB
Revenue Growth (TTM YoY)53.4%11.05%
EPS Growth (TTM YoY)108.9%0%
Qtr Sales Growth53.4%-68.8%
Qtr Profit Growth77.3%59.2%

Profitability & Leverage

MetricSENORESVINEETLAB
ROE13.4%
ROCE15.1%-28%
Net Margin18.5%-26.92%
Operating Margin26.6%-22.4%
Debt to Equity0.37x2.73x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricSENORESVINEETLAB
Promoter Holding39.54% 0.02 pp5.98% 6.48 pp
FII Holding3.64% 0.29 pp0.36% 0.36 pp
DII Holding9.61% 0.3 pp
Public Holding40.93% 0.61 pp93.66% 6.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Senores Pharmaceuticals Limited and Vineet Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.